Qinghaosu (Artemisinin) – Effects and Uses

What is Qinghaosu?

Qinghaosu (also known as artemisinin) is a bioactive natural compound extracted from the plant Artemisia annua (sweet wormwood). The substance was isolated in the 1970s by Chinese scientist Tu Youyou, who was awarded the Nobel Prize in Physiology or Medicine in 2015 for this discovery. Qinghaosu revolutionized the global treatment of malaria and is classified by the World Health Organization (WHO) as an essential medicine.

Origin and History

The use of Artemisia annua in Traditional Chinese Medicine (TCM) dates back more than 2,000 years. Historical texts describe the plant as a remedy for fever. During the Vietnam War, the Chinese government launched a secret research initiative (Project 523) to find new antimalarial treatments. Tu Youyou and her team first isolated the pure compound qinghaosu in 1971 and demonstrated its antiparasitic efficacy.

Mechanism of Action

Qinghaosu contains a rare endoperoxide bridge in its chemical structure. This bridge reacts with iron(II) ions, which are present in high concentrations within the malaria parasite Plasmodium. This reaction generates free radicals that destroy the cell membranes and proteins of the parasite, triggering its cell death. This mechanism is highly selective for parasite cells, which explains the good tolerability of the compound in humans.

Medical Applications

Malaria

Qinghaosu and its derivatives (e.g., artemether, artesunate, dihydroartemisinin) form the basis of artemisinin-based combination therapies (ACTs), recommended by the WHO as first-line treatment for uncomplicated Plasmodium falciparum malaria. Combining artemisinin derivatives with a partner drug (e.g., lumefantrine, mefloquine) is essential to prevent the development of resistance.

Other Areas of Research

Current scientific studies are investigating the potential of qinghaosu and its derivatives in other conditions, including:

• Certain types of cancer (oncological research)
• Autoimmune diseases such as systemic lupus erythematosus (SLE)
• Parasitic infections such as schistosomiasis

These applications are still largely in the experimental stage and have not been approved for routine clinical use.

Dosage and Usage Notes

The dosage of artemisinin-based preparations depends on the specific derivative, the indication, body weight, and the severity of the disease. Artemisinin monotherapies are explicitly not recommended by the WHO due to the risk of resistance. Treatment should always be administered under medical supervision.

Side Effects and Safety

Qinghaosu and its derivatives are generally considered well tolerated. Possible side effects include:

• Nausea and vomiting
• Dizziness
• Headache
• Cardiac arrhythmias (at high doses)
• Rarely: neurological symptoms at very high doses

Use during pregnancy, especially in the first trimester, requires careful benefit-risk assessment by qualified medical personnel.

Resistance Concerns

In some parts of Southeast Asia, particularly in the Mekong region, resistance to artemisinin-based compounds has been observed. This represents a serious threat to global malaria control efforts and underscores the need for the development of new combination therapies.

References

1. World Health Organization (WHO) - Guidelines for the Treatment of Malaria, 3rd Edition (2015). Available at: https://www.who.int
2. Tu Y. - The Discovery of Artemisinin (Qinghaosu) and Gifts from Chinese Medicine. Nature Medicine, 17(10), 1217-1220 (2011).
3. Meshnick SR. - Artemisinin: mechanisms of action, resistance and toxicity. International Journal for Parasitology, 32(13), 1655-1660 (2002).